<DOC>
	<DOCNO>NCT00880490</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy inhale PT005 compare placebo Formoterol Fumarate ( Foradil Aerolizer ) patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Inhaled PT005 Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Signed write informed consent 40 80 year age Fluency write spoken English Females nonchild bear potential female child bear potential negative pregnancy test ; acceptable contraceptive method Current/former smoker least 10 packyear history cigarette smoke A measured postsalbutamol FEV1/FVC ratio &lt; = 0.70 A measured postsalbutamol FEV1 &gt; = 40 &lt; = 80 % predict normal value Demonstrated reversibility short act beta agonist either &gt; 12 % &gt; 150 ml improvement baseline FEV1 , 30 minute follow administration 4 puff salbutamol MDI absolute improvement &gt; 200 ml baseline FEV1 , 30 minute follow administration 4 puff salbutamol MDI . Competent use inhalation device Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray ( CT scan ) due presence COPD Hospitalized due poorly control COPD within 24 week Screening Poorly control COPD prior 6weeks , define occurrence acute worsen COPD require corticosteroid antibiotic acute worsen COPD require treatment prescribe physician Clinically significant medical condition Lower respiratory tract infection require antibiotic past 6 week Clinically significant abnormal ECG Clinically significant uncontrolled hypertension Positive Hepatitis B surface antigen Hepatitis C antibody Cancer complete remission least 5 year History hypersensitivity beta2agonists study drug component History severe milk protein allergy Known suspect history alcohol drug abuse Medically unable withhold short act bronchodilator 8hours Use medication specify time interval prior Screening : 12weeks : depot corticosteroid , intraarticular corticosteroid ; 4 week : ICS &gt; 1000 Î¼g/day fluticasone propionate equivalent , nonpotassium spar diuretic , Pglycoprotein inhibitor , CYP3A4 inhibitor ; 1 week : tiotropium ; 48 hour : oral beta agonist , long act beta agonist , theophylline , zariflukast , montelukast , zileuton ; 8 hour : ipratropium ipratropium/salbutamol combination product , inhale short act beta agonist , xanthine contain food Use follow medication prohibit : tricyclic antidepressant , monoamine oxidase ( MAO ) inhibitor , betaadrenergic antagonist , anticonvulsant ( barbiturate , hydantoin , carbamazepine phenothiazine Receiving longtermoxygen nocturnal oxygen therapy &gt; 12 hour day Diagnosis sleep apnea uncontrolled Participation acute phase pulmonary rehabilitation prior 4 week enter acute phase pulmonary rehabilitation program study Unable comply study procedure Affiliated Investigator site Questionable validity consent A positive drug abuse test Screening life prior Screening , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>